Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
Conditions
HER2 Negative · Low PD-L1 Expressing · Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Binzhou Medical University Hospital, Binzhou, Shandong, China
Contact: Study coordinator (Feng Wang)Dezhou People's Hospital, Dezhou, Shandong, China
Contact: Study coordinator (Tao Li)Shengli Oilfield Central Hospital, Dongying, Shandong, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Contact: Principal Investigator (Lian Liu, MD, PHD)Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Contact: Principal Investigator (Lei Cong, MD)Shandong Provincial Third Hospital, Jinan, Shandong, China
Jinan Central Hospital, Jinan, Shandong, China
Contact: Study coordinator (Meili Sun)Jinan Third People's Hospital, Jinan, Shandong, China
Contact: Study coordinator (Zupeng Luan)Shandong Qianfoshan Hospital, Jinan, Shandong, China
Contact: Study coordinator (Jing Liang)Affiliated Hospital of Jining Medical College, Jining, Shandong, China
Contact: Study coordinator (Junye Wang, MD)Liaocheng People's Hospital, Liaocheng, Shandong, China
Contact: Study coordinator (Baozhong Wang)Linyi Cancer Hospital, Linyi, Shandong, China
Contact: Study coordinator (Zhen Li)Linyi People's Hospital, Linyi, Shandong, China
Contact: Study coordinator (Jinling Zhang)Qilu Hospital of Shandong University(Qingdao), Qingdao, Shandong, China
Qingdao Municipal Hospital, Qingdao, Shandong, China
Contact: Study coordinator (xiaomei Xu)Qingdao Municipal Hospital, Qingdao, Shandong, China
Contact: Study coordinator (Lu Yue)The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Contact: Study coordinator (Ziming Liu)Taian City Central Hospital, Tai’an, Shandong, China
Contact: Study coordinator (Li Meng, MD)The Second Affiliated Hospital of Shandong First Medical University, Tai’an, Shandong, China
Tengzhou Central People's Hospital, Tengzhou, Shandong, China
Weifang Hospital of Traditional Chinese Medicine, Weifang, Shandong, China
Contact: Study coordinator (Zhonghai Du)Weihai Central Hospital, Weihai, Shandong, China
Contact: Study coordinator (Ming Wang)Yantai Yuhuangding Hospital, Yantai, Shandong, China
Yantai Yuhuangding Hospital, Yantai, Shandong, China
Contact: Study coordinator (Ping Sun)Yantaishan Hospital, Yantai, Shandong, China
Zibo Central Hospital, Zibo, Shandong, China
Zibo First People's Hospital, Zibo, Shandong, China
Contact: Study coordinator (Fei Ding)Jining First People's Hospital, Jining, China
Contact: Study coordinator (Jie Li)
Study leads
Lian Liu, MD, PHD
Principal Investigator
Qilu Hospital of Shandong University